(E)-1-bromo-3-methyl-2-pentene | 69297-65-0

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 有机溴化物
• 英文名称: (E)-1-bromo-3-methyl-2-pentene
• 英文别名: (E)-3-methyl-1-bromo-pentene；(E)-1-bromo-3-methyl-pent-2-ene；trans-3-Methylpent-2-enylbromid；(E)-1-bromo-3-methylpent-2-ene
• CAS: 69297-65-0
• 化学式: C₆H₁₁Br
• 分子量: 163.057
• InChiKey: DJZUPHKHXDIJFU-GQCTYLIASA-N

物化性质

• 沸点：
  150.5±9.0 °C(Predicted)
• 密度：
  1?+-.0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  7
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  (E)-1-bromo-3-methyl-2-pentene 在 吡啶 、 sodium hydroxide 、 lithium aluminium tetrahydride 、 phosphate buffer 、 Lipase PS 、 magnesium ethylate 、 sodium hydride 、 碘甲烷 作用下， 以 乙醚 、 乙醇 、 丙酮 为溶剂， 反应 91.0h， 生成 (3R,6E)-3-acetoxy-7-methyl-6-nonene
  参考文献：
  名称：

  Naoshima, Yoshinobu; Munakata, Yoshihito; Funai, Akio, Bioscience, Biotechnology and Biochemistry, 1992, vol. 56, # 6, p. 999 - 1000

  摘要：

  DOI：
• 作为产物：
  描述：

  2-戊烯酸,3-甲基-,(E)- 在 吡啶 、 lithium aluminium tetrahydride 、 三溴化磷 作用下， 以 乙醚 为溶剂， 生成 (E)-1-bromo-3-methyl-2-pentene
  参考文献：
  名称：

  Naoshima, Yoshinobu; Munakata, Yoshihito; Funai, Akio, Bioscience, Biotechnology and Biochemistry, 1992, vol. 56, # 6, p. 999 - 1000

  摘要：

  DOI：

文献信息

• [EN] 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME<br/>[FR] COMPOSÉS DÉRIVÉS DE 1,3,4-OXADIAZOLE UTILISÉS EN TANT QU'INHIBITEUR DE L'HISTONE DÉSACÉTYLASE 6, ET COMPOSITION PHARMACEUTIQUE LES COMPRENANT
  申请人：CHONG KUN DANG PHARMACEUTICAL CORP

  公开号：WO2020022794A1

  公开（公告）日：2020-01-30

  The present invention relates to novel compounds having a histone deacetylase 6 (HDAC6) inhibitory activity, optical isomers thereof or pharmaceutically acceptable salts thereof, a pharmaceutical use thereof, and a method for preparing the same. According to the present invention, the novel compounds, optical isomers thereof or pharmaceutically acceptable salts thereof have the histone deacetylase 6 (HDAC6) inhibitory activity, and are effective in preventing or treating HDAC6-related diseases, comprising infectious diseases; neoplasm; internal secretion; nutritional and metabolic diseases; mental and behavioral disorders; neurological diseases; eye and ocular adnexal diseases; circulatory diseases; respiratory diseases; digestive diseases; skin and subcutaneous tissue diseases; musculoskeletal system and connective tissue diseases; and teratosis or deformities, and chromosomal aberration.

  本发明涉及具有组蛋白去乙酰化酶6（HDAC6）抑制活性的新化合物，其光学异构体或其药学上可接受的盐，其药用用途以及其制备方法。根据本发明，这些新化合物，其光学异构体或其药学上可接受的盐具有组蛋白去乙酰化酶6（HDAC6）抑制活性，并且在预防或治疗与HDAC6相关的疾病方面具有有效性，包括传染病；肿瘤；内分泌；营养和代谢疾病；精神和行为障碍；神经系统疾病；眼部和眼附器疾病；循环系统疾病；呼吸系统疾病；消化系统疾病；皮肤和皮下组织疾病；肌肉骨骼系统和结缔组织疾病；以及畸形或变形和染色体异常。
• [EN] PHOSPHATE-SUBSTITUTED QUINOLIZINE DERIVATIVES USEFUL AS HIV INTEGRASE INHIBITORS<br/>[FR] DÉRIVÉS DE QUINOLIZINE SUBSTITUÉS PAR UN PHOSPHATE UTILES EN TANT QU'INHIBITEURS DE L'INTÉGRASE DU VIH
  申请人：MERCK SHARP & DOHME

  公开号：WO2016154527A1

  公开（公告）日：2016-09-29

  The present invention relates to Phosphate Substituted Quinolizine Derivatives of Formula (I): and pharmaceutically acceptable salts or prodrug thereof, wherein X, Y, R1, R2, R3, R4, R5, R9 and R10 are as defined herein. The present invention also relates to compositions comprising at least one Phosphate Substituted Quinolizine Derivative, and methods of using the Phosphate Substituted Quinolizine Derivatives for treating or preventing HIV infection in a subject.

  本发明涉及公式（I）的磷酸取代喹啉啉衍生物及其药学上可接受的盐或前药，其中X、Y、R1、R2、R3、R4、R5、R9和R10如本文所定义。本发明还涉及包含至少一种磷酸取代喹啉啉衍生物的组合物，以及使用这些磷酸取代喹啉啉衍生物治疗或预防受试者的HIV感染的方法。
• PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF DISEASES INVOLVING IMPOTENCE
  申请人：Kwak Taehwan

  公开号：US20100239674A1

  公开（公告）日：2010-09-23

  Disclosed is a pharmaceutical composition for the treatment and/or prevention of erectile dysfunction, comprising (a) a therapeutically effective amount of a compound represented by Formula 1 or 2, and (b) a pharmaceutically acceptable carrier, a diluent or an excipient, or any combination thereof.

  本发明公开了一种用于治疗和/或预防勃起功能障碍的药物组合物，包括（a）按照式1或式2表示的化合物的治疗有效量，以及（b）药学上可接受的载体、稀释剂或赋形剂，或其任意组合。
• Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease
  申请人：Coburn A. Craig

  公开号：US20070021454A1

  公开（公告）日：2007-01-25

  The present invention is directed to spiropiperidine compounds of formula (I) and tautomers thereof, which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

  本发明涉及式（I）及其互变异构体的螺环吡啶化合物，这些化合物是β-分泌酶酶的抑制剂，并且在治疗β-分泌酶酶参与的疾病，如阿尔茨海默病方面是有用的。本发明还涉及包括这些化合物的制药组合物以及在治疗β-分泌酶酶参与的这些疾病中使用这些化合物和组合物的用途。
• Pharmaceutical Composition for the Treatment or Prevention of Diseases Involving Obesity, Diabetes, Metabolic Syndrome, Neuro-Degenerative Diseases and Mitochondria Dyfunction Diseases
  申请人：Yoo Sang-Ku

  公开号：US20080146655A1

  公开（公告）日：2008-06-19

  Provided is a pharmaceutical composition for the treatment and prevention of obesity, diabetes, metabolic syndromes, degenerative diseases and mitochondrial dysfunction-related diseases, comprising: a therapeutically effective amount of a compound represented by Formula I below, or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, and a pharmaceutically acceptable carrier, a diluent or an excipient, or any combination thereof.

  提供一种药物组合物，用于治疗和预防肥胖、糖尿病、代谢综合征、退行性疾病和线粒体功能障碍相关疾病，包括：以下式I所表示的化合物的治疗有效量，或其药学上可接受的盐、前药、溶剂或异构体，以及药学上可接受的载体、稀释剂或赋形剂，或其任意组合。